Publications by authors named "A S Kartseva"
While the pandemic is behind us, the world community faces a global threat of bacterial resistance outbreak. One of the key ways to combat the spread of multi-resistant bacteria is infection prevention and control tactics using modern antiseptic and disinfectant compositions. Herein, we continue the path to unravel the structure-activity relationship (SAR) of potent pyridine-derived biocide class bis-quaternary ammonium compounds (QACs).
View Article and Find Full Text PDFArticle Synopsis
- Botulinum neurotoxins (BoNTs) are highly potent natural toxins, and neutralizing monoclonal antibodies (MAbs) offer an effective immunotherapy against them, with hybridoma technology being the go-to method for MAb production.
- In this study, researchers isolated plasmablasts and activated memory B-cells from a donor who had received BoNT/A injections, then fused them with a cell line to create hybridomas that produce native human MAbs specific to BoNT/A.
- Three hybridomas were successfully created, one of which (1B9) not only binds effectively to BoNT/A but also inhibits its catalytic activity, showing promise for effective treatment even in cases of low
The new coronavirus infection COVID-19 is an acute viral disease that affects primarily the upper respiratory tract. The etiological agent of COVID-19 is the SARS-CoV-2 RNA virus (Coronaviridae family, Betacoronavirus genus, Sarbecovirus subgenus). We have developed a high-affinity human monoclonal antibody, called C6D7-RBD, which is specific to the S protein receptor-binding domain (RBD) from the SARS-CoV-2 Wuhan-Hu-1 strain and exhibits virus-neutralizing activity in a test with recombinant antigens: angiotensin-converting enzyme 2 (ACE2) and RBD.
View Article and Find Full Text PDFNeutralization of the lethal toxin of Bacillus anthracis is an important topic of both fundamental medicine and practical health care, regarding the fight against highly dangerous infections. We have generated a neutralizing monoclonal antibody 1E10 against the lethal toxin of Bacillus anthracis and described the stages of receptor interaction between the protective antigen (PA) and the surface of eukaryotic cells, the formation of PA oligomers, assembly of the lethal toxin (LT), and its translocation by endocytosis into the eukaryotic cell, followed by the formation of a true pore and the release of LT into the cell cytosol. The antibody was shown to act selectively at the stage of interaction between Bacillus anthracis and the eukaryotic cell, and the mechanism of toxin-neutralizing activity of the 1E10 antibody was revealed.
View Article and Find Full Text PDFArticle Synopsis
- Live anthrax vaccine using attenuated Bacillus anthracis spores is utilized in Russia and CIS countries to prevent anthrax.
- The study examined how long specific antibodies related to spore antigens and protective factors persist in donors after vaccination, and how these levels relate to the ability to neutralize toxins.
- Findings revealed that antibodies can last over a year post-vaccination, with a moderate correlation between antibody levels and neutralization activity in the donors’ blood.